[{"from": "human", "value": "Describe this molecule. [C][C][O][C][=C][Branch2][Ring2][=N][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][N][=C][C][=Branch2][Ring1][=N][=C][Ring1][#Branch1][N][C][=C][C][=Branch2][Ring1][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][O][C][C][=C][C][=C][C][=N][Ring1][=Branch1][Cl][C][#N][N][C][=Branch1][C][=O][/C][=C][/C][N][Branch1][C][C][C]"}, {"from": "gpt", "value": "The molecule is an orally available, 6,7-disubstituted-4-anilinoquinoline-3-carbonitrile irreversible inhibitor of the HER-2 receptor tyrosine kinase with potential antineoplastic activity. Neratinib binds to the HER-2 receptor irreversibly, thereby reducing autophosphorylation in cells, apparently by targeting a cysteine residue in the ATP-binding pocket of the receptor. Treatment of cells with this agent results in inhibition of downstream signal transduction events and cell cycle regulatory pathways; arrest at the G1-S (Gap 1/DNA synthesis)-phase transition of the cell division cycle; and ultimately decreased cellular proliferation. Neratinib also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells."}]